NCT00384228View on ClinicalTrials.gov

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2007

Conditions
Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
Interventions
DRUG

Nilotinib

Trial Locations (1)

Unknown

Novartis Investigative Site, Tokyo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY